

Association between endometrial indoleamine 2,3-dioxygenase expression level and pregnancy outcomes in women undergoing first in vitro fertilization treatment

Su Liu

Shenzhen Zhongshan Urology Hospital

Hongxia Wei

Shenzhen Zhongshan Urology Hospital

Yuye Li

Shenzhen Zhongshan Urology Hospital

Ruochun Lian

Shenzhen Zhongshan Urology Hospital

Xiaohui Wang

Shenzhen Zhongshan Urology Hospital

Lanna Chen

Shenzhen Zhongshan Urology Hospital

Yong Zeng (✉ zengyong1966@gmail.com)

Shenzhen Zhongshan Urology Hospital <https://orcid.org/0000-0002-6264-283X>

Research

Keywords: Indoleamine 2,3-dioxygenase, endometrium, in vitro fertilization, live birth

Posted Date: February 20th, 2020

DOI: <https://doi.org/10.21203/rs.2.24110/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Indoleamine 2,3-dioxygenase (IDO) has been reported to play a key role in placental development during normal pregnancy. However, the question of whether endometrial IDO expression affects in vitro fertilization (IVF) pregnancy outcomes remains unclear. The current study was undertaken to investigate whether there was any association between endometrial IDO expression and IVF treatment outcome.

Methods

This retrospective study was designed to compare pregnancy outcomes among women with different endometrial IDO expression levels under their first IVF treatment. A total of 140 women undergoing their IVF treatment were selected from January 2017 to December 2017. Endometrial samples were collected during mid-luteal phase before IVF cycle. The endometrial IDO expression levels were analyzed by immunohistochemistry, and compared between women who were pregnant or not. A logistic regression analysis was performed to determine the impact of endometrial IDO expression on live birth.

Results

No significant differences in the endometrial IDO expression levels were found between women who had clinical pregnancy and those who failed ($P>0.05$). However, the endometrial IDO expression level was significantly higher among women who had live birth compared with those who had no live birth ($P=0.031$). Additionally, after adjusting for differences in maternal age, BMI and duration of gonadotropin stimulation, women with higher IDO expression level had an increased live birth rate (adjusted odds ratio [aOR] 2.863, 95% confidence interval [CI] 1.180-6.947).

Conclusions

Higher endometrial IDO expression level during mid-luteal phase is associated with an increased live birth rate in women undergoing their first IVF treatment.

Introduction

Infertility, which was defined as failure to establish a successful pregnancy after 12 months of unprotected intercourse or therapeutic donor insemination, affects approximately 1 to 2 hundred million couples of reproductive age worldwide [1, 2]. In vitro fertilization and embryo transfer (IVF-ET) has developed as the primary choice to treat infertility associated with male factors, endometriosis, ovarian dysfunction and other unexplained reasons.

Numerous studies have provided better comprehension of mechanisms that influence fertilization and implantation, however, it still remains a major challenge to find proper biomarkers that may predict pregnancy issues after IVF, which can be assessed before the initiation of treatment. The process of

implantation and the maintenance of normal pregnancy may include mechanisms preventing rejection of the allogeneic fetus. A proportion of studies postulated that the abnormal pregnancy outcomes might be due to immunological dysfunction, but the precise mechanisms for the disturbance of immune tolerance at the fetal-maternal interface are still poorly understood. To maintain normal pregnancy, the immune system is tightly regulated and in part by metabolic pathways [3].

As part of a network of “metabolic immune regulation”, indoleamine 2,3-dioxygenase (IDO) has been reported to play a key role in placental development during normal pregnancy [4, 5]. IDO has diverse biological roles. Firstly, IDO catalyzes the initial and rate-limiting step of tryptophan degradation along the kynurenine pathway, produces immune modulatory tryptophan metabolites, and therefore exhibits immunosuppressive effects [6, 7]. The IDO pathway contributes to Treg differentiation and activation of functional suppressor activity in mature Tregs [8, 9]. Initial evidence for IDO-mediated immunosuppression was demonstrated at the maternal-fetal interface [10]. Inhibition of IDO with the competitive inhibitor results in the rejection of allogeneic fetuses, supporting the role of IDO as a negative regulator of immunity in vivo [10]. Secondly, IDO-induced tryptophan degradation could eliminate invading pathogens by nutrient competition [11]. Thirdly, IDO is also involved in the efficient invasion of the endometrial tissue by trophoblastic cells, which is a prerequisite for the occurrence of a normal pregnancy [12, 13]. These observations suggest that although IDO shares its role with other molecular mediators, it is a key element controlling normal pregnancy.

Accumulating evidences indicate that reduced activity or expression level of IDO may lead to pathological pregnancies. Our previous study showed that the endometrial IDO expression level in women with recurrent miscarriage (RM) was significantly lower than that of normal fertile controls [14]. In term placenta, decreased IDO expression was found to be associated with the severity and onset time of pre-eclampsia [15]. However, the question of whether endometrial IDO expression affects IVF pregnancy outcomes remains unclear. Thus, we investigated IDO protein expression in the mid-luteal phase when endometrium is prepared for implantation and retrospectively analyzed the possible correlation of endometrial IDO expression with characteristics of infertile patients and pregnancy outcomes. The contribution of endometrial IDO expression to live birth was further determined using logistic regression analysis.

Methods

Participants

This was a retrospective cohort study of 140 infertile women who underwent their first IVF cycle in the Fertility Center, Shenzhen Zhongshan Urology Hospital (SZUH) from January 2017 to December 2017. Patients were included if they met the following criteria: 1) age \leq 40 years old; 2) agreed to conduct endometrial biopsy before controlled ovarian hyperstimulation (COH); 3) the endometrial thickness \geq 7 mm on the day of biopsy; 4) the endometrium was in the mid-secretory phase confirmed by hematoxylin and eosin (H&E) staining; 5) the time interval between endometrial biopsy and embryo

transfer was less than 3 months. Patients were excluded if they had: 1) history of medical or surgical abortion; 2) history of IVF-ET treatment; 3) the following adverse factors in the uterine cavity: tuberculosis, endometritis, chocolate cyst of ovary, endometriosis, uterine polyp, adenomyosis, polycystic ovary syndrome (PCOS), uterine scar, hydrosalpinx or endometrial cavity fluid; 4) treated with antagonist protocols. This retrospective study was approved by the reproductive research ethics committees of SZUH (Approval number: SZZSECHU-F-20019037). Informed consent was provided by all subjects at recruitment.

Immunohistochemical And Imaging Analysis

Endometrial tissues were collected using an endometrial curette after 7–9 days of LH surge. After washing with phosphatebuffered saline (PBS), the endometrial samples were fixed with 4% paraformaldehyde 6 to 12 hours at room temperature. Then, all samples were processed into paraffin within 48 hours. Paraffin-embedded endometrial tissues were cut into 4- μm sections followed by deparaffinization and dehydration for immunohistochemistry. The histologic phase was confirmed by H&E staining. IHC staining procedure was performed using BOND-III Fully Automated IHC and ISH Stainer according to the manufacturer's instructions (Leica Biosystems, Wetzlar, Germany). The primary antibody targeted to IDO was purchased from Cell Signaling Technology, Danvers, Massachusetts. Other reagents for IHC were provided by Bond™ Polymer Refine Detection (Catalog No: DS9800) kit. Finally, quantification was analyzed by the Vectra automated quantitative pathology imaging system (Perkin Elmer, Waltham, Massachusetts). Only the images filled with over 80% of tissues were included in the analysis and thirty fields were captured totally for one sample. For IDO, the staining was graded by two observers independently based on both the staining intensity and positivity at a magnification of 200 \times field (0.95 mm²). Grade 1, no cells were stained or stained weakly and scarcely positive; grade 2, the cells were stained moderately and focally positive; grade 3, the cells were stained strongly and diffusely positive [14, 15].

Ivf And Embryo Transfer Protocols

All included patients received a routine luteal phase down-regulation protocol with GnRH agonist protocol. The gonadotropin starting dose and the GnRH analogue were selected based on the physician's discretion. Final oocyte maturation was induced by injection of human chorionic gonadotropin (hCG) when at least two follicles had reached a mean diameter of 18 mm as observed on ultrasound scan. The serum E₂ concentration and endometrial thickness were measured on the day of hCG administration. Oocyte retrieval was carried out 36 hours after ovulation trigger by transvaginal ultrasonographically guided needle aspiration. The oocytes were fertilized by traditional IVF or intracytoplasmic sperm injection (ICSI), according to the oocyte and semen status. Embryo quality was evaluated by two experienced embryologists based on the number of blastomeres as well as the percentage of

fragmentation. Cleavage-stage embryos or blastocysts with good morphological quality were chosen for embryo transfer on day 3 or day 5 after fertilization.

Outcome Measures

The pregnancy outcomes in this study included the implantation, clinical pregnancy, miscarriage, and live birth rates. The implantation rate was calculated as number of intrauterine gestational sacs per total number of transferred embryos. Clinical pregnancy was defined as the observation of a gestational sac under ultrasonography 4 to 5 weeks after embryo transfer. Miscarriage was defined as fetus loss within the first 12 gestational weeks. Live birth rate was calculated as cycles with delivered live babies per embryo transfer cycle.

Statistical analysis

Descriptive statistical analysis was performed on main maternal and cycle characteristics. Continuous data with normal distribution were presented as the mean \pm standard deviation (SD) and analyzed by independent t-test. The continuous variables that did not show a normal distribution were presented as median and interquartile range, and were analyzed by Mann-Whitney U-test. Categorical data were presented by the number of cases and corresponding percentage, and were analyzed by Pearson's χ^2 test or Fisher's exact test. To assess the relationships between endometrial IDO expression levels and different pregnancy outcomes, logistic regression analysis, adjusted for maternal age and BMI, were performed. All P values are two sided and statistical significance was established as $P < 0.05$. All analyses were conducted using SPSS (version 23.0; SPSS Inc.).

Results

Immunohistochemical grading of IDO expression in the endometrium

Based on immunohistochemical staining, IDO was mainly localized in surface epithelial cells, glandular epithelial cells and a small number of cells within the stromal compartment (including stromal cells and leukocytes) in endometrium (Fig. 1). According to the previous studies, immunostaining grading scale was used to evaluate the expression levels of IDO in all the patients included. The grading was performed based on staining intensity and positivity, as described in the Materials and Methods section: grade 1 (no or weak staining and scarcely positive); grade 2 (moderately stained and focally positive); grade 3 (strongly stained and diffusely positive).

Population Characteristics

During the study period, 140 couples receiving their first IVF-ET treatments formed the present study population, including 36 women with grade 1 endometrial IDO expression, 46 women with grade 2 endometrial IDO expression, and 58 women with grade 3 endometrial IDO expression.

Table 1 depicts patient and IVF cycle characteristics by pregnancy outcome. Clinical pregnancy rate was 64.3% and live birth rate was 57.1% in our study population. Baseline patient characteristics including age, BMI, baseline serum FSH level, infertility duration and diagnosis were compared among the different groups. No significant differences were noted. Clinical pregnancy was associated with lower dose of gonadotropin used ($P = 0.046$), whereas live birth was associated with shorter duration of gonadotropin stimulation ($P = 0.039$).

Association Of Ido Expression And Pregnancy Outcomes

There was no significant difference on the endometrial IDO expression level between women who had clinical pregnancy and those who failed ($P > 0.05$). However, the endometrial IDO expression level was significantly higher among women who had live birth compared with those who had no live birth ($P = 0.031$) (Fig. 2).

A binary logistic regression analysis was performed to analyze the association between endometrial IDO expression and live birth (Table 2). As indicated in Table 2, more live births were positively correlated with higher endometrial IDO expression. After adjusted for maternal age and BMI, women with grade 3 IDO expression still had a higher live birth rate (aOR 2.857, 95% CI 1.184–6.891, $P = 0.019$). Moreover, a secondary analysis was performed including age, BMI and duration of gonadotropin stimulation in the model, which did not substantially alter the estimates, live birth remained positively associated with an increased endometrial IDO expression (aOR 2.863, 95% CI 1.180–6.947, $P = 0.020$).

Discussion

In the present study, we found that endometrial IDO expression was positively associated with more live birth among women during their first IVF treatment, after adjusting for important confounders. Our results suggest that IDO might play a functional role in predicting live birth among women in their first IVF treatment.

A successful pregnancy depends on the regulation of maternal immune system at the maternal-fetal interface to enable a functional placenta to develop. Thus, the semiallogenic fetus is tolerated by the mother and protected by a very efficient process of immune tolerance during the entire process. Since Munn et al. [10] formulated the hypothesis that the expression of IDO at the maternal-fetal interface could prevent immunological rejection of the fetal allograft, there have been many studies on the physiological significance of IDO in human pregnancy. The role of IFO in regulating maternal-fetal tolerance is attributed to its immunosuppressive properties, which are based on inhibition of T cell proliferation through deletion of the essential amino acid tryptophan since T cells exhibit a tryptophan-sensitive G1

cell cycle arrest [16]. Our previous study showed that the expression level of IDO was downregulated in RM patients compared with controls, suggesting an important role of IDO in the maintenance of normal pregnancy [14]. Furthermore, the production of IFN- γ , which is an important and potent stimulator of IDO expression, is found to be significantly decreased in RM patients, which may lead to the reduction in IDO and its activity [17]. Previous studies have demonstrated a link between IDO and preeclampsia [15]. IDO expression was significantly downregulated in preeclampsia placenta, and the reduction in IDO expression was associated with the severity of maternal hypertension and proteinuria. Thus, IDO may play an important role in maintaining a healthy pregnancy.

In our study, endometrial IDO expression starts in the mid-luteal phase around the time when embryo implantation is expected. Thus, this early IDO expression at maternal-fetal interface may be considered as preparation of the endometrium for maternal establishment for fetal tolerance and the regulation of trophoblast invasion.

It is unclear why we failed to see any relationship between IDO expression levels and clinical pregnancy and miscarriage rates. This result can be partially explained by the recent postulation that the first trimester of pregnancy is associated with inflammation, which is required for blastocyst implantation [18]. Pregnancy can be divided into three distinct immunological processes characterized by different biological processes. During the first stage, the blastocyst has to break through the epithelial lining of the uterus and damage the endometrial tissue in order to implant; then the trophoblast must replace the endothelium and vascular smooth muscle of the maternal blood vessels to secure an adequate placental-fetal blood supply. Thus, the first trimester of pregnancy can be viewed as a pro-inflammatory phase. Consistently, higher IDO expression was not associated with higher clinical pregnancy rate and lower miscarriage rate in our study.

Although we have concluded that endometrial IDO expression was positively correlated with live birth in infertile patients seeking IVF-ET treatment, several limitations should be further considered. First, this is a retrospective study, so a well-designed randomized controlled study should be conducted to verify these results. Second, our study did not include frozen-thawed ET cycles, which may induce some unknown bias. Third, well-designed clinical studies are warranted to elucidate the pathogenesis of IDO expression and its subsequent effects on IVF success.

In conclusion, our data suggest that an elevated level of endometrial IDO expression is associated with an increased rate of live birth in IVF treatment. The endometrial IDO expression may also be a new therapeutic target for better IVF treatment, however, further large prospective study are required to verify this hypothesis.

Abbreviations

IDO:indoleamine 2,3-dioxygenase; IVF-ET:in vitro fertilization and embryo transfer; RM:recurrent miscarriage; COH:controlled ovarian hyperstimulation; PCOS:polycystic ovary syndrome;

PBS:phosphatebuffered saline; hCG:human chorionic gonadotropin; ICSI:intracytoplasmic sperm injection; BMI:body mass index; E₂:estradiol; EMT:endometrial thickness.

Declarations

Acknowledgements

We would like to thank the staff at the Fertility Center at Shenzhen Zhongshan Urology Hospital for recruiting patients and helping with samples.

Author contribution statement

S.L. conceived the study and wrote the paper. H.W. and X.W. performed experiments and analyzed data. R.L. performed the data collection. Y.Z. and Y.L. contributed to the critical discussion, interpretation and editing of the manuscript.

Funding

This work was supported by Basic Research Program of Shenzhen (JCYJ20170307140647669), Science and Technology Project of Health and Family Planning Commission of Shenzhen Municipality (SZBC2018003), Natural Science Foundation of Guangdong Province (2019A15150109), National Key Research & Developmental Program of China (2018YFC1003900) and Sanming Project of Medicine in Shenzhen (SZSM201502035).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This study was approved by the Reproductive Research Ethics Committees of Shenzhen Urology Hospital (Approval number: SZZSECHU-F-20019037).

Consent for publication

Written informed consent for publication was obtained from the patients.

Competing interests

The authors declare that they have no competing interests.

References

1. Practice Committee of American Society for Reproductive M: **Definitions of infertility and recurrent pregnancy loss: a committee opinion.** *Fertil Steril* 2013, **99**:63.

2. Inhorn MC, Patrizio P: **Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century.** *Hum Reprod Update* 2015, **21**:411-426.
3. Gerriets VA, Rathmell JC: **Metabolic pathways in T cell fate and function.** *Trends Immunol* 2012, **33**:168-173.
4. Kudo Y, Boyd CA, Sargent IL, Redman CW: **Decreased tryptophan catabolism by placental indoleamine 2,3-dioxygenase in preeclampsia.** *Am J Obstet Gynecol* 2003, **188**:719-726.
5. Mellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D, Munn DH: **Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy.** *Nat Immunol* 2001, **2**:64-68.
6. Katz JB, Muller AJ, Prendergast GC: **Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.** *Immunol Rev* 2008, **222**:206-221.
7. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC: **Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.** *Nat Med* 2005, **11**:312-319.
8. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH: **Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.** *J Clin Invest* 2007, **117**:2570-2582.
9. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, et al: **The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells.** *J Immunol* 2006, **176**:6752-6761.
10. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL: **Prevention of allogeneic fetal rejection by tryptophan catabolism.** *Science* 1998, **281**:1191-1193.
11. Adams O, Besken K, Oberdorfer C, MacKenzie CR, Takikawa O, Daubener W: **Role of indoleamine-2,3-dioxygenase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections.** *J Virol* 2004, **78**:2632-2636.
12. Kamimura S, Eguchi K, Yonezawa M, Sekiba K: **Localization and developmental change of indoleamine 2,3-dioxygenase activity in the human placenta.** *Acta Med Okayama* 1991, **45**:135-139.
13. Sedlmayr P: **Indoleamine 2,3-dioxygenase in materno-fetal interaction.** *Curr Drug Metab* 2007, **8**:205-208.
14. Wei H, Liu S, Lian R, Huang C, Li Y, Chen L, Zeng Y: **Abnormal Expression of Indoleamine 2, 3-Dioxygenase in Human Recurrent Miscarriage.** *Reprod Sci* 2019:1933719119833788.
15. Iwahashi N, Yamamoto M, Nanjo S, Toujima S, Minami S, Ino K: **Downregulation of indoleamine 2, 3-dioxygenase expression in the villous stromal endothelial cells of placentas with preeclampsia.** *J Reprod Immunol* 2017, **119**:54-60.
16. Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL: **Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division.** *Immunology* 2002, **107**:452-460.

17. Miwa N, Hayakawa S, Miyazaki S, Myojo S, Sasaki Y, Sakai M, Takikawa O, Saito S: **IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-gamma increase in normal pregnancy but decrease in spontaneous abortion.** *Mol Hum Reprod* 2005, **11**:865-870.
18. Mor G, Aldo P, Alvero AB: **The unique immunological and microbial aspects of pregnancy.** *Nat Rev Immunol* 2017, **17**:469-482.

Tables

Due to technical limitations, Tables 1 & 2 are only available for download from the Supplementary Files section.

Figures

Figure 1




Figure 1

Immunohistochemical grading of the expression of IDO in endometrium. The grading was performed based on staining intensity and positivity, as described in the materials and methods, grade 1: no or weak staining and scarcely positive, IDO was localized in the stromal compartment (A); grade 2: moderately stained and focally positive, IDO was localized in surface epithelial cells (B); grade 3: strongly stained and diffusely positive, IDO was localized in glandular epithelial cells (C); scale bars = 100 µm, with insets = 10 µm.

Figure 2




Figure 2

Comparison of endometrial IDO expression between different groups. (A) The statistical chart showing the expression level of IDO in endometrium between the non-pregnant group (n=50) and pregnant group (n=90). (B) The statistical chart showing the expression level of IDO in endometrium between the non-live birth group (n=60) and live birth group (n=80). *P < 0.05, Mann-Whitney U test.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [TABLE1.docx](#)
- [TABLE2.docx](#)